CKD 382
Alternative Names: CKD-382Latest Information Update: 28 Oct 2023
Price :
$50 *
At a glance
- Originator Chong Kun Dang
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gastro-oesophageal reflux
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Gastro-oesophageal-reflux(In volunteers) in South Korea (PO, Tablet)
- 07 Oct 2021 Chong Kun Dang Pharmaceutical initiates a phase I trial in healthy volunteers in South Korea (NCT05108038)
- 25 Sep 2020 Phase-I clinical trials in Gastro-oesophageal reflux (In volunteers) in South Korea (PO, Tablet) (NCT04703374)